Status:
RECRUITING
Higher vs. Lower Dose Heparin for PCI
Lead Sponsor:
Population Health Research Institute
Conditions:
Cardiovascular Diseases
Percutaneous Coronary Intervention
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
HD PCI is a multicenter, randomized, registry-based, cluster crossover design trial of higher dose versus lower dose heparin in patients undergoing elective percutaneous coronary intervention (PCI).
Detailed Description
The primary objective of HD PCI is to compare the effect of a policy of higher dose heparin (100 U/kg) use to a policy of lower dose heparin (70 U/kg) use on death, myocardial infarction (MI) or targe...
Eligibility Criteria
Inclusion
- \- Patients undergoing elective PCI
Exclusion
- Age \<18 years
- Planned chronic total occlusion PCI
- Non-resident precluding follow up through local registries
- Hospital (Cluster) Eligibility Criteria
- Hospitals will be eligible to participate if they meet the following criteria:
- Submit PCI procedure data to a compatible registry that is able to provide data for the trial
- Site agrees to manage patients as per the higher or lower dose heparin policy in place during the given crossover period
Key Trial Info
Start Date :
March 2 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2025
Estimated Enrollment :
16000 Patients enrolled
Trial Details
Trial ID
NCT04049591
Start Date
March 2 2022
End Date
December 1 2025
Last Update
July 31 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hamilton Health Sciences, General Hospital
Hamilton, Ontario, Canada, L8L 2X2